Opinion

Video

BCG-Unresponsive NMIBC and Treatments

Author(s):

Mark D. Tyson, MD, MPH,Gary D. Steinberg, MD

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options include cystectomy, intravesical chemotherapy, immunotherapy, or clinical trials.

Video content above is prompted by the following:

  • When do you consider a patient to have BCG-unresponsive disease?
  • What treatment options are available for BCG-unresponsiveness/intolerance in patients?
Related Videos
2 experts in this video
Timothy Lyon, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
1 expert is featured in this series.
Medcast series
Related Content
Key FDA decisions urologists can expect in the first half of 2025
January 28th 2025

Key FDA decisions urologists can expect in the first half of 2025

Hannah Clarke
Check out the key regulatory decisions set to happen early this year.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma
January 22nd 2025

UGN-101 offers durable RFS in low-grade upper tract urothelial carcinoma

Hannah Clarke
"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options
January 17th 2025

Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options

Fed Ghali, MD
“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
Anktiva targets expanded indication in US and global approvals in EU and UK
January 16th 2025

Anktiva targets expanded indication in US and global approvals in EU and UK

Hannah Clarke
The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.
© 2025 MJH Life Sciences

All rights reserved.